Research Paper Volume 12, Issue 14 pp 14406—14417

Osthole resensitizes CD133+ hepatocellular carcinoma cells to cisplatin treatment via PTEN/AKT pathway

class="figure-viewer-img"

Figure 6. Osthole attenuated the cisplatin resistance of CD133 positive HCC in vivo. (A) Growth curve of CD133+ Huh7 originated tumors on nude mice which were treated with cisplatin (8 mg/kg) and osthole (20 mg/kg) twice a week. (B) Separated tumor tissues from nude mice after euthanasia. (C) The final weight of separated tumor tissues from nude mice after euthanasia. *P<0.05 vs. osthole treatment group, #P<0.05 vs. cisplatin treatment group. (D) Expression of PTEN in purified tumor tissues was tested by western blot analysis. (E) Activation of caspase-9 and caspase-3 in purified tumor tissues was tested by western blot analysis.